何種現行準則是最適合台灣新診斷攝護腺癌症安排全身骨掃瞄檢查的依據
錢祖明1,呂研嫚1,柯宏龍1,2,黃書彬1,2, 黃俊農1,2
1高雄醫學大學 附設中和紀念醫院 泌尿科
2高雄醫學大學 醫學系
The most ideal guidelines for performing bone scans in prostate cancer staging in taiwan
Tsu-Ming Chien1, Yen-Man Lu1, Hung-Lung Ke1,2, Shu-Pin Huang1,2, Chun-Nung Huang1,2
1Division of Urology,
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
2School of Medicine,
Kaohsiung Medical University, Kaohsiung, Taiwan
Purpose: The necessity of bone scans in newly diagnosed prostate cancer patients is still a matter of debate. We attempt to evaluate the validity of currently published guidelines by analyzing bone scan results in newly diagnosed prostate cancer (PCa) patients to determine the optimal staging strategies.
Materials and Methods: Between January 2011 and July 2014, there were 362 consecutive newly diagnosed PCa patients at Kaohsiung Medical University Hospital. Bone scans were performed for all patients at initial staging. Patients positive for bone metastasis were characterized at diagnosis in terms of age, prostate-specific antigen (PSA) level, Gleason score (GS), and clinical stage. We analyzed the sensitivity and specificity of the American Urological Association (AUA) best practice policy, European Association of Urology guidelines, National Comprehensive Cancer Network guidelines, and the classification and regression tree by Briganti et al. for diagnostic performance in predicting bone metastasis.
Results: A total 73 of 362 (20.2%) patients were diagnosed with bone metastasis. Patients positive for metastasis on bone scans had significantly higher PSA levels (943.6 ± 2198.4 ng/mL vs. 56.1 ± 183.1 ng/mL; p < 0.001) and higher GSs (8.5 ± 1.0 vs. 7.0 ± 1.6; p < 0.001) than those with negative bone scan results. Pairwise comparisons in receiver operating curve analysis demonstrated that the AUA guidelines had a larger area under the curve than did the other guidelines.
Conclusion: The current AUA guidelines for the recommendation of staging bone scans had better prediction and application rates than other guidelines in our patient cohort.